Fintepla
Named-patient access overview. Fintepla is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Fintepla (fenfluramine) is UCB's oral antiseizure medication for Dravet syndrome and Lennox-Gastaut syndrome, two of the most severe and treatment-resistant childhood epileptic encephalopathies. It received FDA approval in 2020 for Dravet and 2022 for Lennox-Gastaut. The drug operates under a REMS program in the US because of historical cardiovascular concerns from its prior use as an appetite suppressant. For Saudi Arabia families with a child with confirmed Dravet or LGS, this page describes the SFDA Personal Importation Program pathway.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Fintepla
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Fintepla is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Fintepla in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Fintepla
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.